Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03222895 · ClinicalTrials.gov registry record
Distribution of Lymph Node Metastases in Esophageal Carcinoma
A clinical trial of Esophageal Neoplasms and Lymph Node Metastases, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 19
- Study locations
NCT03222895 is a study of Esophageal Neoplasms and Lymph Node Metastases that is actively recruiting participants, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). The registered enrollment target is 5,000 participants, above the 1,072-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (366% higher). The trial reports 19 study locations across 3 states.
The verdict
NCT03222895, a study of Esophageal Neoplasms and Lymph Node Metastases, is actively recruiting participants, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 19
- Study locations
Study Summary
Background: Lymph node status is an important prognostic parameter in esophageal carcinoma and an independent predictor of survival. Distribution of metastatic lymph nodes may vary with tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy. Surgical strategy depends on the distribution pattern of nodal metastases but consensus on the extent of lymphadenectomy differs worldwide. Especially for adenocarcinoma the distribution of lymph node metastases has not yet been described in large series. Aim of the present study is to evaluate the distribution of lymph node metastases in esophageal carcinoma specimens following transthoracic esophagectomy with at least a 2-field lymphadenectomy. Methods: The TIGER-study is a multinational observational cohort study. All patients with a resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed in participating centers will be included. All lymph node stations will be excised and separately sent for pathological examination. Cluster analysis will be performed to identify patterns of metastases in relation to tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy. Conclusion: TIGER will provide a roadmap of the location of lymph node metastases in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and survival. Patient-tailored treatment can be developed on the basis of these results, such as the the optimal radiation field and extent of lymphadenectomy based on the primary tumor characteristics.
Conditions Studied
Study Locations (19)
Other
- Instituto Nacional de Câncer - Rio de Janeiro
- University of Toronto - Toronto
- Hospital District of Helsinki and Uusimaa - Helsinki
- University Medical Center of the Johannes Gutenberg University - Mainz
- University of Athens, School of Medicine - Athens
- University of Hong Kong - Hong Kong
- Tata Memorial Centre - Mumbai
- IRCCS Policlinico San Donato - Milan
- Ospedale San Raffaele - Milan
- University of Verona - Verona
- Uonuma Institute and Niigata University - Niigata
- Keio University School of Medicine - Tokyo
- The Cancer Institute Hospital of JFCR - Tokyo
- Ziekenhuisgroep Twente, Almelo & Hengelo - Almelo
- Amsterdam UMC - Amsterdam
- Hospital Universitario del Mar - Barcelona
- Karolinska Institutet - Stockholm
Texas
- MD Anderson Cancer Center - Houston
Yangpu
- Fudan University Shanghai Cancer Center - Shanghai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2028-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03222895
The ClinicalTrials.gov registry entry for NCT03222895 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,072-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (366% higher). The listed sponsor is Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Esophageal Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT03222895 reports 19 study locations spanning 3 distinct geographic areas - top geographies include Other, Texas, Yangpu.
Frequently Asked Questions
What is clinical trial NCT03222895 about?
NCT03222895 is a clinical study titled "Distribution of Lymph Node Metastases in Esophageal Carcinoma". Background: Lymph node status is an important prognostic parameter in esophageal carcinoma and an independent predictor of survival. Distribution of metastatic lymph nodes may vary with tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy. Surgical strategy depends on the di...
What is the current status of trial NCT03222895?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2019-03-01. Estimated completion is 2028-06-01.
What conditions does trial NCT03222895 study?
This clinical trial studies the following conditions: Esophageal Neoplasms, Lymph Node Metastases.
Who is sponsoring clinical trial NCT03222895?
This trial is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03222895 being conducted?
This trial has 19 study locations across Texas, Yangpu. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
RECRUITING
-
Mayo Clinic Upper Digestive Disease Survey
RECRUITING
-
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RECRUITING · Phase 1
-
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.